Small Interfering RNAs (siRNAs) Therapeutics Market Size to Reach USD 1,987.5 million in 2032

KOLKATA, India - Dec. 3, 2025 - PRLog -- Advancements in drug delivery technologies are showing great potential to enhance siRNA-based therapies, paving the way for a new class of pharmaceuticals nano-siRNA drugs. Unlike small molecule therapeutics and monoclonal antibodies, it provides a distinct advantage by precisely silencing target genes through complete Watson-Crick base pairing with mRNA.

In March 2025, Alnylam Pharmaceuticals, Inc., a leader in RNA interference therapeutics, announced that the Food and Drug Administration approved Qfitlia, sixth RNAi to be approved in the U.S.

Segments market overview and growth Insights
Therapeutic siRNA drugs segment contributed the largest share in 2024. The clinical application of RNA interference (RNAi) biological mechanisms has enabled the emergence of a new and growing class of RNA-based therapies.

Regional market overview and growth insights

North America held the largest market share in the Small Interfering RNAs (siRNAs) Therapeutics market in 2024. The market is being driven by rising prevalence of genetic and rare diseases, advancements in RNA delivery technologies.

Get a preview of the complete research study:

https://navistratanalytics.com/report_store/small-interfe...